NCT04478656View on ClinicalTrials.gov

Safety and Immunogenicity of BBV121

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 3, 2017

Primary Completion Date

November 15, 2017

Study Completion Date

November 15, 2018

Conditions
Zika Virus Infection
Interventions
BIOLOGICAL

BBV121

BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28

Trial Locations (1)

500078

Bharat Biotech International Ltd, Hyderabad

All Listed Sponsors
lead

Bharat Biotech International Limited

INDUSTRY

NCT04478656 - Safety and Immunogenicity of BBV121 | Biotech Hunter | Biotech Hunter